P356Evaluation of the long‐term cost‐effectiveness of treatment switching from sitagliptin to liraglutide in subjects with Type 2 diabetes in the United KingdomA BARNETT1,2, G Subramanian3, S Arnoldini4, B Hunt4 and C Stentoft Hoxer31Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK, 2Heart of England NHS Foundation Trust, Birmingham, UK, 3Novo Nordisk Ltd., Gatwick, UK, 4Ossian Health Economics and Communications, Basel, SwitzerlandObjectives: The recent LIRA‐SWITCH trial showed that treatment switching from sitagliptin 100mg to liraglutide 1.8mg led to statistically significant and clinically relevant improvements in HbA1c and body mass index. The aim of this study was to assess the long‐term cost‐effectiveness of treatment switching from sitagliptin to liraglutide 1.8mg in patients with Type 2 diabetes in the United Kingdom.Methods: The QuintilesIMS CORE Diabetes Model Version 8.5+ (QuintilesIMS Health, Basel, Switzerland) was used to project costs and clinical outcomes over patients’ lifetimes. Baseline cohort characteristics and treatment effects were based on the randomised controlled LIRA‐SWITCH trial. Both future costs and clinical benefits were discounted at 3.5% per annum. Costs were accounted in pounds sterling (GBP [£]) and expressed in 2016 values.Results: Model projections showed improved quality‐adjusted life expectancy for patients with poor glycaemic control (HbA1c 7.5% to 9.5%) on
Diabetic Medicine – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera